Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 101 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2016, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.

Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 18 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.Vancomycin-Resistant Enterococcus faecium Infections.

Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Vancomycin-Resistant Enterococcus faecium Infections Overview 9
Therapeutics Development 10
Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Overview 10
Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis 11
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Development by Companies 12
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Investigation by Universities/Institutes 14
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Vancomycin-Resistant Enterococcus faecium Infections - Products under Development by Companies 17
Vancomycin-Resistant Enterococcus faecium Infections - Products under Investigation by Universities/Institutes 19
Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development 20
Alchemia Limited 20
Alvogen Korea Co., Ltd. 21
Aphios Corporation 22
C3 Jian, Inc 23
Cellceutix Corporation 24
Helix BioMedix, Inc. 25
Hsiri Therapeutics LLC 26
LegoChem Biosciences, Inc 27
Lytix Biopharma AS 28
MGB Biopharma Limited 29
MicuRx Pharmaceuticals, Inc. 30
Nanotherapeutics, Inc. 31
NovoBiotic Pharmaceuticals, LLC 32
Oragenics, Inc. 33
Sealife PHARMA GMBH 34
Sentinella Pharmaceuticals, Inc. 35
TAXIS Pharmaceuticals, Inc. 36
Wockhardt Limited 37
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
AM-218 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
BDM-I - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
brilacidin tetrahydrochloride - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
chrysophaentin - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
closthioamide - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Epimerox - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
HB-1345 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
HT-01 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
HT-02 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
IBN-1 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
LCB-010371 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
LCB-010699 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
LTX-109 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Marinus - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
MGBBP-3 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
MRX-I - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
MRX-IV - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
NAI-107 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
NAI-108 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
NAI-603 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
OG-253 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
ramoplanin - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
SLP-0904 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
SLP-0905 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Small Molecules for Bacterial Infections - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Small Molecules to Inhibit Glycosyltransferase for Bacterial Infections - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
SP-2078 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Synthetic Peptides for Vancomycin Resistant Enterococci Infections - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Teixobactin - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
WCK-4086 - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects 95
Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products 96
Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones 97
Featured News & Press Releases 97
Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I 97
Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project 97
Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140 98
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 98
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I 99
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 100
Disclaimer 101

List of Tables

Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H2 2016 10
Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 (Contd..1) 18
Products under Investigation by Universities/Institutes, H2 2016 19
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Alchemia Limited, H2 2016 20
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Alvogen Korea Co., Ltd., H2 2016 21
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Aphios Corporation, H2 2016 22
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by C3 Jian, Inc, H2 2016 23
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Cellceutix Corporation, H2 2016 24
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Helix BioMedix, Inc., H2 2016 25
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics LLC, H2 2016 26
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by LegoChem Biosciences, Inc, H2 2016 27
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Lytix Biopharma AS, H2 2016 28
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MGB Biopharma Limited, H2 2016 29
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2016 30
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Nanotherapeutics, Inc., H2 2016 31
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2016 32
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Oragenics, Inc., H2 2016 33
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sealife PHARMA GMBH, H2 2016 34
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H2 2016 35
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H2 2016 36
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Wockhardt Limited, H2 2016 37
Assessment by Monotherapy Products, H2 2016 38
Number of Products by Stage and Target, H2 2016 40
Number of Products by Stage and Mechanism of Action, H2 2016 42
Number of Products by Stage and Route of Administration, H2 2016 44
Number of Products by Stage and Molecule Type, H2 2016 46
Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H2 2016 95
Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products, H2 2016 96